(Q34395747)

1 August 2017

title

Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia (English)

1 reference

1 August 2017

1 reference

D Symmons

4

0 references

Herman Waldmann

7

object named as

H Waldmann

1 reference

1 August 2017

8

G Hale

1 reference

1 August 2017

J D Isaacs

1

1 reference

1 August 2017

S Greer

2

1 reference

1 August 2017

S Sharma

3

1 reference

1 August 2017

M Smith

5

1 reference

1 August 2017

J Johnston

6

1 reference

1 August 2017

B L Hazleman

9

1 reference

1 August 2017

publication date

1 September 2001

1 reference

1 August 2017

published in

Arthritis & Rheumatology

1 reference

1 August 2017

volume

44

1 reference

1 August 2017

issue

9

1 reference

1 August 2017

page(s)

1998-2008

1 reference

Mechanisms of peripheral tolerance and suppression induced by monoclonal antibodies to CD4 and CD8.

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200109%2944%3A9%3C1998%3A%3AAID-ART348%3E3.0.CO%3B2-T

Long-term immunomodulatory effects of T lymphocyte depletion in patients with systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200109%2944%3A9%3C1998%3A%3AAID-ART348%3E3.0.CO%3B2-T

Campath-1H therapy in refractory ocular inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200109%2944%3A9%3C1998%3A%3AAID-ART348%3E3.0.CO%3B2-T

Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200109%2944%3A9%3C1998%3A%3AAID-ART348%3E3.0.CO%3B2-T

CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200109%2944%3A9%3C1998%3A%3AAID-ART348%3E3.0.CO%3B2-T

CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200109%2944%3A9%3C1998%3A%3AAID-ART348%3E3.0.CO%3B2-T

Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200109%2944%3A9%3C1998%3A%3AAID-ART348%3E3.0.CO%3B2-T

EULAR register of patients on immunosuppressive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200109%2944%3A9%3C1998%3A%3AAID-ART348%3E3.0.CO%3B2-T

The mortality of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200109%2944%3A9%3C1998%3A%3AAID-ART348%3E3.0.CO%3B2-T

The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200109%2944%3A9%3C1998%3A%3AAID-ART348%3E3.0.CO%3B2-T

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200109%2944%3A9%3C1998%3A%3AAID-ART348%3E3.0.CO%3B2-T

Unexplained opportunistic infections and CD4+ T-lymphocytopenia without HIV infection. An investigation of cases in the United States. The Centers for Disease Control Idiopathic CD4+ T-lymphocytopenia Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200109%2944%3A9%3C1998%3A%3AAID-ART348%3E3.0.CO%3B2-T

Cause of death in patients with rheumatoid arthritis with particular reference to azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200109%2944%3A9%3C1998%3A%3AAID-ART348%3E3.0.CO%3B2-T

T cell homeostasis in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200109%2944%3A9%3C1998%3A%3AAID-ART348%3E3.0.CO%3B2-T

Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200109%2944%3A9%3C1998%3A%3AAID-ART348%3E3.0.CO%3B2-T

Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200109%2944%3A9%3C1998%3A%3AAID-ART348%3E3.0.CO%3B2-T

Changes in thymic function with age and during the treatment of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200109%2944%3A9%3C1998%3A%3AAID-ART348%3E3.0.CO%3B2-T

Apheresis biotechnology and the rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200109%2944%3A9%3C1998%3A%3AAID-ART348%3E3.0.CO%3B2-T

Total lymphoid irradiation in patients with refractory rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200109%2944%3A9%3C1998%3A%3AAID-ART348%3E3.0.CO%3B2-T

The CAMPATH-1 antigen (CDw52)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200109%2944%3A9%3C1998%3A%3AAID-ART348%3E3.0.CO%3B2-T

Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200109%2944%3A9%3C1998%3A%3AAID-ART348%3E3.0.CO%3B2-T

Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200109%2944%3A9%3C1998%3A%3AAID-ART348%3E3.0.CO%3B2-T

Autologous blood stem cell transplantation for autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200109%2944%3A9%3C1998%3A%3AAID-ART348%3E3.0.CO%3B2-T

High-dose immunosuppressive therapy for rheumatoid arthritis: some answers, more questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200109%2944%3A9%3C1998%3A%3AAID-ART348%3E3.0.CO%3B2-T

Humanised monoclonal antibody therapy for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200109%2944%3A9%3C1998%3A%3AAID-ART348%3E3.0.CO%3B2-T

Arthro-osteitis--a clinical spectrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200109%2944%3A9%3C1998%3A%3AAID-ART348%3E3.0.CO%3B2-T

A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200109%2944%3A9%3C1998%3A%3AAID-ART348%3E3.0.CO%3B2-T

Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200109%2944%3A9%3C1998%3A%3AAID-ART348%3E3.0.CO%3B2-T

The European Commission and health care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200109%2944%3A9%3C1998%3A%3AAID-ART348%3E3.0.CO%3B2-T

Total lymphoid irradiation in rheumatoid arthritis. A ten-year followup

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200109%2944%3A9%3C1998%3A%3AAID-ART348%3E3.0.CO%3B2-T

Survivorship and Death in Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200109%2944%3A9%3C1998%3A%3AAID-ART348%3E3.0.CO%3B2-T

Survival, prognosis, and causes of death in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200109%2944%3A9%3C1998%3A%3AAID-ART348%3E3.0.CO%3B2-T

T cells in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200109%2944%3A9%3C1998%3A%3AAID-ART348%3E3.0.CO%3B2-T

Treatment of refractory rheumatoid arthritis with a chimeric anti-CD4 monoclonal antibody. Long-term followup of CD4+ T cell counts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200109%2944%3A9%3C1998%3A%3AAID-ART348%3E3.0.CO%3B2-T

Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200109%2944%3A9%3C1998%3A%3AAID-ART348%3E3.0.CO%3B2-T

Intensified-dose (4 gm/m2) cyclophosphamide and granulocyte colony-stimulating factor administration for hematopoietic stem cell mobilization in refractory rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200109%2944%3A9%3C1998%3A%3AAID-ART348%3E3.0.CO%3B2-T

10.1002/1529-0131(200109)44:9<1998::AID-ART348>3.0.CO;2-T

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference